Women with early-stage hormone receptor (HR)-positive breast cancer who had low to intermediate scores on the Oncotype DX Breast Recurrence Score assay did just as well on neoadjuvant endocrine ...
A retrospective study validates the Oncotype 21-gene breast recurrence score as a predictive biomarker of adjuvant chemotherapy benefit in women with estrogen receptor (ER)-positive/human epidermal ...
Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth ...
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer ...
A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score ® result provides more accurate estimates about that ...
Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions The feasibility of Oncotype DX ...
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results